Orthocell reports 98.6% success rate in Striate+â„¢ dental membrane study
May 15, 2024 at 02:46 pm
Share
(via NewsDirect)
Orthocell Ltd (ASX:OCC, OTC:ORHHF) CEO and managing director Paul Anderson joins Jonathan Jackson in the Proactive studio to talk through a 98.6% success rate in a post-market clinical study examining the effectiveness of its Striate+™ dental membrane in guided bone regeneration for dental implants. The Striate+™, a resorbable collagen membrane, has been validated through this study as a leading solution in bone and tissue regeneration, supporting Orthocell’s claim of its product being the best choice for such medical procedures. Anderson highlights the membrane's ability to enable high-quality bone and tissue repair, crucial for functional and aesthetically pleasing outcomes in patients. These results, indicating a notable level of bone formation and stability, were obtained from 99 patients, reinforcing the product's efficacy in real-world applications. Orthocell anticipates that the success of the Striate+™ will enhance its visibility among dental professionals and support BioHorizons, its exclusive global distributor, in increasing the product's market adoption. This development is particularly significant given the estimated annual market potential of more than US$700 million for the Striate+ product. The findings are scheduled for presentation at the European Association for Osseintegration (EAO) annual meeting in October 2024. The study also contributes to the clinical data needed for re-certification of EU market approval under the new European Medical Device Regulations (MDR), following an earlier Post-Market Clinical Follow-up (PMCF) study.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source Press Releases
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. It is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
ORTHOCELL LIMITED 
